PUBLISHER: Mellalta Meets LLP | PRODUCT CODE: 1170397
PUBLISHER: Mellalta Meets LLP | PRODUCT CODE: 1170397
The Anti-CCR8 report covers the anti-CCR8 market opportunity providing Key Competitive Analysis, 18+ Companies with Pipeline Drug Profiles, Clinical Trials, Other Developments (Collaboration Details, Funding, etc.), Licensing and Agreements, Business Agreements, Business Partners as well as Clinical Partner. The report covers pipeline product analysis by stage of development, competitive landscape by phases, companies, therapy area, and indication by phases. The Anti-CCR8 report adds value in terms of describing clinical-stage products concerning their clinical & regulatory timelines as well as in terms of providing the current market opportunity, drivers, and challenges.
The Anti-CCR8-mediated Treg depletion specifically in tumor tissues for a limited period could avoid deleterious autoimmunity and immunopathology in mice, despite CCR8 expression by some tissue-resident Tregs (46). This lack of immunological adverse effects can be attributed not only to the selective depletion of tumor-reactive Tregs by anti-CCR8 mAb but also to the differences in the antigenicity of normal self-antigens versus quasi-self-tumor antigens, and the differences between the tumor microenvironment and the normal tissue.
In this report, Mellalta Meets provides an in-depth analysis of Anti-CCR8 covering discovery, preclinical and clinical studies, details of partnerships and business deal values, targeted technologies and therapy areas, investments, and acquisition trends. Currently, there are more than 17 candidate Anti-CCR8 products currently under evaluation in clinical and preclinical studies. The major key players operating in the market are Bristol-Myers Squibb, Shionogi, LaNova Medicines, InnoCare Pharma/Keymed Biosciences, Bayer, and many more which have robust clinical pipelines of Anti-CCR8 candidates.
As per analysis, the development pipeline is full of molecules like small molecules, antibodies, and combination therapies.